外周血标志物在非小细胞肺癌免疫治疗中的研究进展

doi:10.3760/cma.j.cn371439-20250110-00028

摘要/Abstract

摘要：

免疫治疗已在非小细胞肺癌（NSCLC）中取得了较为理想的效果，但并非所有患者都能从中获益。基于外周血的标志物易获取、可动态监测，外周血肿瘤细胞相关标志物（循环肿瘤DNA、循环肿瘤细胞、外周血肿瘤突变负荷、外泌体等）、免疫及炎症标志物（T淋巴细胞亚群、血常规相关比值、C反应蛋白等）在免疫治疗疗效预测、预后评估和动态监测方面显示出巨大潜力。

关键词: 癌, 非小细胞肺, 生物标记, 肿瘤, 免疫疗法

Abstract:

Immunotherapy has achieved relatively satisfactory results in the treatment of non-small cell lung cancer （NSCLC），but not all patients can benefit from immunotherapy. Peripheral blood-based markers are easily accessible and can be monitored dynamically. Peripheral blood tumor cell-related markers （circulating tumor DNA，circulating tumor cells，peripheral blood tumor mutation load，exosomes，etc.），as well as immune and inflammatory markers （T-lymphocyte subpopulations，hematology-associated ratios，C-reactive protein，etc.） have demonstrated great potential in immunotherapy efficacy prediction，prognosis evaluation，and dynamic monitoring.

Key words: Carcinoma, non-small-cell lung, Biomarkers, tumor, Immunotherapy

王智颖, 盛立军. 外周血标志物在非小细胞肺癌免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(3): 180-185.

Wang Zhiying, Sheng Lijun. Research progress of peripheral blood biomarkers in immunotherapy of non-small cell lung cancer[J]. Journal of International Oncology, 2025, 52(3): 180-185.

参考文献 47

[1]	Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends[J]. Nat Rev Clin Oncol, 2023, 20(9): 624-639. DOI: 10.1038/s41571-023-00798-3. pmid: 37479810
[2]	Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. DOI: 10.1016/j.jncc.2024.01.006.
[3]	Tang S, Qin C, Hu H, et al. Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects[J]. Cells, 2022, 11(3): 320. DOI: 10.3390/cells11030320.
[4]	Ricciuti B, Jones G, Severgnini M, et al. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)[J]. J Immunother Cancer, 2021, 9(3): e001504. DOI: 10.1136/jitc-2020-001504.
[5]	Pellini B, Chaudhuri AA. Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent[J]. J Clin Oncol, 2022, 40(6): 567-575. DOI: 10.1200/JCO.21.01929. pmid: 34985936
[6]	Liu SY, Dong S, Yang XN, et al. Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase Ⅱ study[J]. Signal Transduct Target Ther, 2023, 8(1): 442. DOI: 10.1038/s41392-023-01700-4.
[7]	Moding EJ, Liu YF, Nabet BY, et al. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer[J]. Nat Cancer, 2020, 1(2): 176-183. DOI: 10.1038/s43018-019-0011-0.
[8]	Wang Y, Wang W, Zhang T, et al. Dynamic bTMB combined with residual ctDNA improves survival prediction in locally advanced NSCLC patients with chemoradiotherapy and consolidation immunotherapy[J]. J Natl Cancer Cent, 2024, 4(2): 177-187. DOI: 10.1016/j.jncc.2024.01.008.
[9]	Provencio M, Serna-Blasco R, Nadal E, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage ⅢA non-small-cell lung cancer (NADIM phase Ⅱ trial)[J]. J Clin Oncol, 2022, 40(25): 2924-2933. DOI: 10.1200/JCO.21.02660. pmid: 35576508
[10]	Murray JC, Sivapalan L, Hummelink K, et al. Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer[J]. Clin Cancer Res, 2024, 30(2): 389-403. DOI: 10.1158/1078-0432.CCR-23-1469.
[11]	Jin F, Zhu L, Shao J, et al. Circulating tumour cells in patients with lung cancer universally indicate poor prognosis[J]. Eur Respir Rev, 2022, 31(166): 220151. DOI: 10.1183/16000617.0151-2022.
[12]	Wankhede D, Grover S, Hofman P. Circulating tumor cells as a predictive biomarker in resectable lung cancer: a systematic review and meta-analysis[J]. Cancers (Basel), 2022, 14(24): 6112. DOI: 10.3390/cancers14246112.
[13]	Mondelo-Macía P, García-González J, León-Mateos L, et al. Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab[J]. Mol Oncol, 2021, 15(11): 2923-2940. DOI: 10.1002/1878-0261.13094. pmid: 34465006
[14]	Purcell E, Niu Z, Owen S, et al. Circulating tumor cells reveal early predictors of disease progression in patients with stage Ⅲ NSCLC undergoing chemoradiation and immunotherapy[J]. Cell Rep, 2024, 43(2): 113687. DOI: 10.1016/j.celrep.2024.113687.
[15]	Spiliotaki M, Neophytou CM, Vogazianos P, et al. Dynamic monito-ring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab[J]. Mol Oncol, 2023, 17(5): 792-809. DOI: 10.1002/1878-0261.13317.
[16]	Papadaki MA, Sotiriou AI, Vasilopoulou C, et al. Optimization of the enrichment of circulating tumor cells for downstream phenotypic analysis in patients with non-small cell lung cancer treated with anti-PD-1 immunotherapy[J]. Cancers (Basel), 2020, 12(6): 1556. DOI: 10.3390/cancers12061556.
[17]	Lin D, Shen L, Luo M, et al. Circulating tumor cells: biology and clinical significance[J]. Signal Transduct Target Ther, 2021, 6(1): 404. DOI: 10.1038/s41392-021-00817-8.
[18]	Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab[J]. Nat Med, 2018, 24(9): 1441-1448. DOI: 10.1038/s41591-018-0134-3. pmid: 30082870
[19]	Kim ES, Velcheti V, Mekhail T, et al. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial[J]. Nat Med, 2022, 28(5): 939-945. DOI: 10.1038/s41591-022-01754-x.
[20]	Si H, Kuziora M, Quinn KJ, et al. A blood-based assay for assessment of tumor mutational burden in first-line metastatic NSCLC treatment: results from the MYSTIC study[J]. Clin Cancer Res, 2021, 27(6): 1631-1640. DOI: 10.1158/1078-0432.CCR-20-3771. pmid: 33355200
[21]	Jiang T, Chen J, Xu X, et al. On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase Ⅲ trial[J]. Mol Cancer, 2022, 21(1): 4. DOI: 10.1186/s12943-021-01479-4. pmid: 34980131
[22]	Wang Z, Duan J, Wang G, et al. Allele frequency-adjusted blood-based tumor mutational burden as a predictor of overall survival for patients with NSCLC treated with PD-(L)1 inhibitors[J]. J Thorac Oncol, 2020, 15(4): 556-567. DOI: 10.1016/j.jtho.2019.12.001. pmid: 31843683
[23]	Ai X, Jia B, He Z, et al. Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432)[J]. Signal Transduct Target Ther, 2024, 9(1): 350. DOI: 10.1038/s41392-024-02060-3.
[24]	Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes[J]. Science, 2020, 367(6478): eaau6977. DOI: 10.1126/science.aau6977.
[25]	Yang Q, Chen M, Gu J, et al. Novel biomarkers of dynamic blood PD-L1 expression for immune checkpoint inhibitors in advanced non-small-cell lung cancer patients[J]. Front Immunol, 2021, 12: 665133. DOI: 10.3389/fimmu.2021.665133.
[26]	Wang Y, Niu X, Cheng Y, et al. Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients[J]. Clin Exp Immunol, 2022, 208(3): 316-322. DOI: 10.1093/cei/uxac045. pmid: 35514075
[27]	Akbar S, Raza A, Mohsin R, et al. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients[J]. Front Immunol, 2023, 13: 1097117. DOI: 10.3389/fimmu.2022.1097117.
[28]	Peng XX, Yu R, Wu X, et al. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer[J]. J Immunother Cancer, 2020, 8(1): e000376. DOI: 10.1136/jitc-2019-000376.
[29]	Steier Z, Kim EJY, Aylard DA, et al. The CD4 versus CD8 T cell fate decision: a multiomics-informed perspective[J]. Annu Rev Immunol, 2024, 42(1): 235-258. DOI: 10.1146/annurev-immunol-083122-040929. pmid: 38271641
[30]	Kagamu H, Kitano S, Yamaguchi O, et al. CD4⁺ T-cell immunity in the peripheral blood correlates with response to anti-PD-1 therapy[J]. Cancer Immunol Res, 2020, 8(3): 334-344. DOI: 10.1158/2326-6066.CIR-19-0574.
[31]	Wu SG, Ho CC, Yang JC, et al. Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: a phase Ⅱ study with immune cell profile analysis[J]. Clin Transl Med, 2025, 15(1): e70149. DOI: 10.1002/ctm2.70149.
[32]	Kim CG, Hong MH, Kim KH, et al. Dynamic changes in circulating PD-1⁺CD8⁺ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer[J]. Eur J Cancer, 2021, 143: 113-126. DOI: 10.1016/j.ejca.2020.10.028.
[33]	Guo W, Qiao T, Li H, et al. Peripheral CD8⁺PD-1⁺ T cells as novel biomarker for neoadjuvant chemoimmunotherapy in humanized mice of non-small cell lung cancer[J]. Cancer Lett, 2024, 597: 217073. DOI: 10.1016/j.canlet.2024.217073.
[34]	Han J, Duan J, Bai H, et al. TCR repertoire diversity of peripheral PD-1⁺CD8⁺ T cells predicts clinical outcomes after immunotherapy in patients with non-small cell lung cancer[J]. Cancer Immunol Res, 2020, 8(1): 146-154. DOI: 10.1158/2326-6066.CIR-19-0398.
[35]	Altan M, Li R, Li Z, et al. High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC[J]. J Immunother Cancer, 2024, 12(12): e008950. DOI: 10.1136/jitc-2024-008950.
[36]	Huang SW, Jiang W, Xu S, et al. Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials[J]. Signal Transduct Target Ther, 2024, 9(1): 285. DOI: 10.1038/s41392-024-01988-w.
[37]	Banna GL, Cortellini A, Cortinovis DL, et al. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1≥50% advanced non-small-cell lung cancer[J]. ESMO Open, 2021, 6(2): 100078. DOI: 10.1016/j.esmoop.2021.100078.
[38]	Nguyen CTT, Van TNK, Huong PT. Predictability of neutrophile to lymphocyte ratio and platelet to lymphocyte ratio on the effectiveness of immune checkpoint inhibitors in non-small cell lung cancer patients: a meta-analysis[J]. Cancer Control, 2024, 31: 10732748241285474. DOI: 10.1177/10732748241285474.
[39]	Sugimoto A, Kaneda H, Yoshimoto N, et al. Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer[J]. Sci Rep, 2024, 14(1): 19596. DOI: 10.1038/s41598-024-70214-y. pmid: 39179598
[40]	Ksienski D, Wai ES, Alex D, et al. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab[J]. Transl Lung Cancer Res, 2021, 10(1): 355-367. DOI: 10.21037/tlcr-20-541.
[41]	Takada K, Takamori S, Yoneshima Y, et al. Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy[J]. Lung Cancer, 2020, 145: 18-26. DOI: 10.1016/j.lungcan.2020.04.034. pmid: 32388276
[42]	Ye X, Dai M, Xiang Z. Prognostic role of systemic inflammation response index in patients with non-small cell lung cancer: a meta-analysis[J]. BMJ Open, 2024, 14(11): e087841. DOI: 10.1136/bmjopen-2024-087841.
[43]	Veccia A, Dipasquale M, Kinspergher S, et al. Prognostic role of inflammatory and nutritional biomarkers in non-small-cell lung cancer patients treated with immune checkpoint inhibitors alone or in combination with chemotherapy as first-line[J]. Cancers (Basel), 2024, 16(22): 3871. DOI: 10.3390/cancers16223871.
[44]	Tong W, Xu H, Tang J, et al. Inflammatory factors are associated with prognosis of non-small cell lung cancer patients receiving immunotherapy: a meta-analysis[J]. Sci Rep, 2024, 14(1): 26102. DOI: 10.1038/s41598-024-76052-2. pmid: 39478006
[45]	Zheng X, Zhang L, Wu L, et al. Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study[J]. BMC Cancer, 2023, 23(1): 1244. DOI: 10.1186/s12885-023-11737-x. pmid: 38104105
[46]	Klümper N, Saal J, Berner F, et al. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer[J]. J Immunother Cancer, 2022, 10(3): e004024. DOI: 10.1136/jitc-2021-004024.
[47]	Naqash AR, McCallen JD, Mi E, et al. Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer[J]. J Immunother Cancer, 2023, 11(10): e007310. DOI: 10.1136/jitc-2023-007310.